FDA v. Utah Medical
This article was originally published in The Gray Sheet
Executive Summary
Aug. 30 trial date set for Salt Lake City federal court to hear Department of Justice's Aug. 9, 2004 complaint seeking to halt firm's sales after an FDA inspection cited persistent QSR deviations at Midvale, Utah facility dating to 2001 (1"The Gray Sheet" Aug. 16, 2004, p. 6)...
You may also be interested in...
Utah Medical Upholds Product Safety, Questions FDA Inspector Credentials
Utah Medical Products will challenge during pre-trial discovery whether FDA's inspectional observations of the Midvale, Utah facility can be construed as QSR violations
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.